Hoshino M, Akitsu K, Kubota K, et al. - Researchers examined the link between clinical results with pulmonary function and biomarkers in prior to as well as following house dust mite (HDM) sublingual immunotherapy (SLIT). Participants were 112 patients experiencing asthma sensitized to HDM. These participants were randomly assigned to add‐on 6 standardized quality‐HDM SLIT to pharmacotherapy or pharmacotherapy alone for 48 weeks. Experts evaluated biomarkers, blood eosinophils, serum IgE, serum periostin, fractional exhaled nitric oxide (FeNO), and spirometry and clinical symptoms, at the baseline as well as close of study. They assessed the link between biomarkers and a rise in FEV₁ of 120 mL or greater. Findings demonstrated that decreased serum periostin and FeNO and improved pulmonary function were achieved by adding HDM SLIT to pharmacotherapy. Experts concluded the likely usefulness of serum periostin and FeNO as biomarkers for prediction of SLIT.